Designed to provide broad exposure to the Health Care ETFs category of the market, the iShares Biotechnology ETF (IBB Quick QuoteIBB - Free Report) is a smart beta exchange traded fund launched on 02/05/2001.

What Are Smart Beta ETFs?

The ETF industry has long been dominated by products based on market cap weighted indexes, a strategy created to reflect the market or a particular market segment.

Market cap weighted indexes work great for investors who believe in market efficiency. They provide a low-cost, convenient and transparent way of replicating market returns.

However, some investors believe in the possibility of beating the market through exceptional stock selection, and choose a different type of fund that tracks non-cap weighted strategies: smart beta.

These indexes attempt to select stocks that have better chances of risk-return performance, based on certain fundamental characteristics or a combination of such characteristics.

Even though this space provides many choices to investors--think one of the simplest methodologies like equal-weighting and more complicated ones like fundamental and volatility/momentum based weighting--not all have been able to deliver first-rate results.

Fund Sponsor & Index

Because the fund has amassed over $10.5 billion, this makes it one of the largest ETFs in the Health Care ETFs. IBB is managed by Blackrock. IBB, before fees and expenses, seeks to match the performance of the Nasdaq Biotechnology Index.

The ICE Biotechnology Index contains securities of NASDAQ listed companies that are classified as either biotechnology or pharmaceuticals.

Cost & Other Expenses

Investors should also pay attention to an ETF's expense ratio. Lower cost products will produce better results than those with a higher cost, assuming all other metrics remain the same.

Annual operating expenses for IBB are 0.44%, which makes it on par with most peer products in the space.

It has a 12-month trailing dividend yield of 0.20%.

Sector Exposure and Top Holdings

Most ETFs are very transparent products, and disclose their holdings on a daily basis. ETFs also offer diversified exposure, which minimizes single stock risk, though it's still important for investors to research a fund's holdings.

This ETF has heaviest allocation in the Healthcare sector - about 100% of the portfolio.

Looking at individual holdings, Amgen Inc (AMGN) accounts for about 8.63% of total assets, followed by Vertex Pharmaceuticals (VRTX) and Gilead Sciences Inc (GILD).

IBB's top 10 holdings account for about 45.96% of its total assets under management.

Performance and Risk

The ETF return is roughly 23.89% and is up about 51.48% so far this year and in the past one year (as of 08/31/2026), respectively. IBB has traded between $138.22 and $216.96 during this last 52-week period.

IBB has a beta of 0.70 and standard deviation of 20.59% for the trailing three-year period, which makes the fund a high risk choice in the space. With about 252 holdings, it effectively diversifies company-specific risk .

Alternatives

iShares Biotechnology ETF is a reasonable option for investors seeking to outperform the Health Care ETFs segment of the market. However, there are other ETFs in the space which investors could consider.

First Trust NYSE Arca Biotechnology ETF (FBT) tracks NYSE Arca Biotechnology Index and the State Street SPDR S&P Biotech ETF (XBI) tracks S&P Biotechnology Select Industry Index. First Trust NYSE Arca Biotechnology ETF has $2.92 billion in assets, State Street SPDR S&P Biotech ETF has $11.69 billion. FBT has an expense ratio of 0.55% and XBI changes 0.35%.

Investors looking for cheaper and lower-risk options should consider traditional market cap weighted ETFs that aim to match the returns of the Health Care ETFs

Bottom Line

To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center.